JP2024514009A5 - - Google Patents

Info

Publication number
JP2024514009A5
JP2024514009A5 JP2023563841A JP2023563841A JP2024514009A5 JP 2024514009 A5 JP2024514009 A5 JP 2024514009A5 JP 2023563841 A JP2023563841 A JP 2023563841A JP 2023563841 A JP2023563841 A JP 2023563841A JP 2024514009 A5 JP2024514009 A5 JP 2024514009A5
Authority
JP
Japan
Prior art keywords
alkyl
nhc
heteroaryl
cycloalkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023563841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514009A (ja
JP7600433B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025364 external-priority patent/WO2022225941A1/en
Publication of JP2024514009A publication Critical patent/JP2024514009A/ja
Publication of JP2024514009A5 publication Critical patent/JP2024514009A5/ja
Priority to JP2024199756A priority Critical patent/JP2025015696A/ja
Application granted granted Critical
Publication of JP7600433B2 publication Critical patent/JP7600433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023563841A 2021-04-21 2022-04-19 カルボキシ-ベンズイミダゾールglp-1r調節化合物 Active JP7600433B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024199756A JP2025015696A (ja) 2021-04-21 2024-11-15 カルボキシ-ベンズイミダゾールglp-1r調節化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163177778P 2021-04-21 2021-04-21
US63/177,778 2021-04-21
US202163286475P 2021-12-06 2021-12-06
US63/286,475 2021-12-06
PCT/US2022/025364 WO2022225941A1 (en) 2021-04-21 2022-04-19 Carboxy-benzimidazole glp-1r modulating compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199756A Division JP2025015696A (ja) 2021-04-21 2024-11-15 カルボキシ-ベンズイミダゾールglp-1r調節化合物

Publications (3)

Publication Number Publication Date
JP2024514009A JP2024514009A (ja) 2024-03-27
JP2024514009A5 true JP2024514009A5 (cg-RX-API-DMAC10.html) 2024-04-15
JP7600433B2 JP7600433B2 (ja) 2024-12-16

Family

ID=81654570

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023563841A Active JP7600433B2 (ja) 2021-04-21 2022-04-19 カルボキシ-ベンズイミダゾールglp-1r調節化合物
JP2024199756A Pending JP2025015696A (ja) 2021-04-21 2024-11-15 カルボキシ-ベンズイミダゾールglp-1r調節化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024199756A Pending JP2025015696A (ja) 2021-04-21 2024-11-15 カルボキシ-ベンズイミダゾールglp-1r調節化合物

Country Status (26)

Country Link
US (2) US11858918B2 (cg-RX-API-DMAC10.html)
EP (2) EP4691554A3 (cg-RX-API-DMAC10.html)
JP (2) JP7600433B2 (cg-RX-API-DMAC10.html)
KR (2) KR20260110277A (cg-RX-API-DMAC10.html)
CN (1) CN117279905B (cg-RX-API-DMAC10.html)
AU (2) AU2022263410B2 (cg-RX-API-DMAC10.html)
BR (1) BR112023021561A2 (cg-RX-API-DMAC10.html)
CA (1) CA3216163A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003119A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023013757A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230495A (cg-RX-API-DMAC10.html)
DK (1) DK4271672T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2023000232A (cg-RX-API-DMAC10.html)
ES (1) ES3071339T3 (cg-RX-API-DMAC10.html)
FI (1) FI4271672T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20260177T1 (cg-RX-API-DMAC10.html)
IL (1) IL306110A (cg-RX-API-DMAC10.html)
LT (1) LT4271672T (cg-RX-API-DMAC10.html)
MX (1) MX2023012418A (cg-RX-API-DMAC10.html)
PE (1) PE20240362A1 (cg-RX-API-DMAC10.html)
PH (1) PH12023552860A1 (cg-RX-API-DMAC10.html)
PL (1) PL4271672T3 (cg-RX-API-DMAC10.html)
PT (1) PT4271672T (cg-RX-API-DMAC10.html)
SI (1) SI4271672T1 (cg-RX-API-DMAC10.html)
TW (2) TWI919156B (cg-RX-API-DMAC10.html)
WO (1) WO2022225941A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
SI4097097T1 (sl) 2020-01-29 2025-04-30 Gilead Sciences, Inc. Spojine, ki modulirajo glp-1r
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
US12180197B2 (en) 2021-03-11 2024-12-31 Gilead Sciences, Inc. GLP-1R modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
LT4271672T (lt) 2021-04-21 2026-03-10 Gilead Sciences, Inc. Karboksibenzimidazolo junginiai, moduliuojantys glp-1r
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
CR20250178A (es) 2022-11-16 2025-06-06 Lilly Co Eli Agonistas del receptor del péptido-1 similar al glucagón
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2024212742A1 (zh) * 2023-04-10 2024-10-17 上海研健新药研发有限公司 一种glp-1r激动剂,其制备方法和应用
EP4731245A1 (en) * 2023-06-23 2026-04-29 Merck Sharp & Dohme LLC Use of a long-acting oxyntomodulin derivative for treament of fatty liver disease
WO2025021048A1 (zh) * 2023-07-21 2025-01-30 石药集团中奇制药技术(石家庄)有限公司 一类多环化合物及其用途
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026033382A1 (en) * 2024-08-07 2026-02-12 Pfizer Inc. Heterocyclic glp-1r modulators
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008015A2 (en) 1998-08-07 2000-02-17 Applied Research Systems Ars Holding N.V. Fsh mimetics for the treatment of infertility
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US20030134853A1 (en) 2001-09-26 2003-07-17 Priestley Eldon Scott Compounds useful for treating hepatitis C virus
CA2523743A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2004108672A1 (en) 2003-06-02 2004-12-16 Abbott Laboratories Isoindolin-1-one compounds as kinase inhibitors
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用
EP1844043A2 (en) 2004-11-18 2007-10-17 The Institutes for Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids for the treatment of diabetes
EP1838690A2 (en) 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
PL1940786T3 (pl) 2005-09-16 2010-12-31 Arrow Therapeutics Ltd Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
WO2007115077A2 (en) 2006-03-31 2007-10-11 Astrazeneca Ab Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
EA018225B1 (ru) 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
WO2010029299A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivaties for use as medicaments
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
WO2011156655A2 (en) 2010-06-09 2011-12-15 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators
AU2011270994B2 (en) 2010-06-24 2015-12-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
CN103059014B (zh) 2011-10-21 2016-05-18 北京韩美药品有限公司 新型杂芳基氨基衍生物
CN104080767A (zh) 2011-12-12 2014-10-01 瑞塞普托斯公司 新的glp-1受体调节剂
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
WO2016018701A1 (en) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
KR20160066490A (ko) 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
US20170035881A1 (en) 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
MX2018011716A (es) 2016-03-30 2019-02-18 Ishihara Sangyo Kaisha Compuesto de piridazinona o su sal, y herbicida que lo contiene.
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CA3058182A1 (en) 2017-03-27 2018-10-04 Cardurion Pharmaceuticals, Llc Heterocyclic compound
EP3681499A4 (en) 2017-09-13 2021-04-21 D.E. Shaw Research, LLC CONNECTIONS AS RAS INHIBITORS AND THEIR USE
WO2019217165A1 (en) 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
CA3045644C (en) 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
FI3806855T3 (fi) 2018-06-15 2023-05-04 Pfizer Glp-1 -reseptorin agonisteja ja niiden käyttöjä
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
EA202191432A1 (ru) 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CN112294760B (zh) 2019-07-26 2025-12-12 宁波新致生物科技有限公司 一种液体制剂及其应用
WO2021018023A1 (zh) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CR20220178A (es) * 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
KR102841983B1 (ko) 2019-11-04 2025-08-04 주식회사 엘지화학 광변조 디바이스의 제조 방법
ES3029360T3 (en) 2019-11-15 2025-06-24 Ildong Pharmaceutical Co Ltd Glp-1 receptor agonist and use thereof
EP4069686B1 (en) 2019-12-02 2025-01-22 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
SI4097097T1 (sl) 2020-01-29 2025-04-30 Gilead Sciences, Inc. Spojine, ki modulirajo glp-1r
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
CN115697999A (zh) 2020-02-13 2023-02-03 加舒布鲁姆生物公司 杂环glp-1激动剂
MX2022011349A (es) 2020-03-18 2022-11-10 Lg Chemical Ltd Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo.
MX2022010811A (es) 2020-03-27 2022-09-27 Pfizer Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo.
CN113493447B (zh) 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
PT4157832T (pt) 2020-05-27 2024-07-30 Qilu Regor Therapeutics Inc Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos
PH12022553313A1 (en) 2020-06-04 2023-04-12 Hangzhou Sciwind Biosciences Co Ltd Five-membered heteroaromatic imidazole compound and use thereof
CN113816948B (zh) 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
TW202214622A (zh) 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Glp-1r促效劑及其用途
JP2023538408A (ja) 2020-08-21 2023-09-07 ターンズ・ファーマシューティカルズ・インコーポレイテッド Glp-1r作動薬としての化合物
CN115515956B (zh) 2020-09-29 2024-06-25 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN116348464B (zh) 2020-10-12 2026-06-16 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022111624A1 (zh) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CA3211349A1 (en) 2021-03-09 2022-09-15 Basf Se Tricyclic pesticidal compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
US12180197B2 (en) 2021-03-11 2024-12-31 Gilead Sciences, Inc. GLP-1R modulating compounds
US20240300928A1 (en) 2021-04-08 2024-09-12 Lg Chem, Ltd. Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
EP4271674B9 (en) 2021-04-21 2026-03-11 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
LT4271672T (lt) 2021-04-21 2026-03-10 Gilead Sciences, Inc. Karboksibenzimidazolo junginiai, moduliuojantys glp-1r
CN117098758A (zh) 2021-06-24 2023-11-21 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
CN113480534B (zh) 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
IL312132A (en) 2021-11-30 2024-06-01 Kura Oncology Inc Macrocyclic compounds having farnesyltransferase inhibitory activity

Similar Documents

Publication Publication Date Title
JP2024514010A5 (cg-RX-API-DMAC10.html)
HRP20250415T1 (hr) Modulirajući spojevi karboksi-benzimidazola glp-1r
JP2023513272A5 (cg-RX-API-DMAC10.html)
JP2023540609A5 (cg-RX-API-DMAC10.html)
JP2023546054A5 (cg-RX-API-DMAC10.html)
JP2023540558A5 (cg-RX-API-DMAC10.html)
JP2023546055A5 (cg-RX-API-DMAC10.html)
JP2023515404A5 (cg-RX-API-DMAC10.html)
ES2713566T3 (es) Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
JP2019069940A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
US20120046305A1 (en) Methods and compositions for treating respiratory disorders
JP2019517478A5 (cg-RX-API-DMAC10.html)
AU2011237421B2 (en) Inverse agonists and neutral antagonists for the TSH receptor
JP2018530571A5 (cg-RX-API-DMAC10.html)
TWI224102B (en) Serotonergic agents
JP2007519753A5 (cg-RX-API-DMAC10.html)
KR20110067096A (ko) 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20160115149A1 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
KR20090088854A (ko) 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
JP2015536973A (ja) PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物
JP2022501429A5 (cg-RX-API-DMAC10.html)
TWI842924B (zh) Gpr119致效劑及dpp-4抑制劑的藥物組合及藥物套組
TWI568733B (zh) 新穎的唏及1,1a,2,7b-四氫環丙烷[c]唏吡啶并吡化合物
CN121985948A (zh) Glp-1r激动剂的制剂及其制备方法
JP2023500685A5 (cg-RX-API-DMAC10.html)